Blood components separator disk

Information

  • Patent Grant
  • 9393576
  • Patent Number
    9,393,576
  • Date Filed
    Thursday, June 25, 2015
    9 years ago
  • Date Issued
    Tuesday, July 19, 2016
    7 years ago
Abstract
A separator disk for use in centrifugal separation of components is designed to automatically position itself during separation at the interface between the supernatant and the remaining components. Preferably the interface is between plasma and red blood cells.
Description
BACKGROUND

Centrifugal separation of blood into components of different specific gravities, such as red blood cells, white blood cells, platelets, and plasma is known from U.S. Pat. No. 5,707,331 (Wells). The apparatus shown in that patent employs a disposable processing tube having two chambers, and blood to be separated into components is placed in one of the chambers. The processing tube is placed in a centrifuge, which subjects the blood to centrifugal forces to separate the components. The supernatant is then automatically decanted into the second of the chambers.


To retain, principally, the red blood cells during the decant of the supernatant, the apparatus disclosed in the Wells patent includes a shelf placed in the first chamber at the expected level of the interface between the red blood cells and the less-dense components, including the plasma. One problem with the arrangement shown in the '331 Wells patent, however, is that the position of the interface varies with the particular proportions of the components (e. g., the hematocrit) of the blood to be processed. Thus, if the shelf is placed at the expected position of the interface for blood of average hematocrit, and the hematocrit of the particular blood being processed is low, the shelf will be above the interface after separation. Such a position of the shelf will hinder the flow of the components near the interface during decanting, thus retaining significant amounts of these components in the first chamber and reducing the separation efficiency of the system.


SUMMARY OF THE INVENTION

In accordance with the invention, a movable separator disk, which automatically positions itself at the interface between the separated components, is placed in the first chamber. In the preferred embodiment, the disk is capable of moving vertically and is designed to position itself automatically at the interface between red blood cells and the remaining components in the centrifugal separation of blood.


Decant of the supernatant can be either by gravity drain or by centrifugal transfer, and a main function of the disk is to restrict the flow of the component below it, e. g., red blood cells, during decant. This ensures that the supernatant is not contaminated and increases the efficiency of the process.


The invention contemplates two embodiments for the disk. In one embodiment, the disk is supported on a central shaft such that an annulus is formed between the perimeter of the disk and the interior surface of the first chamber. The dimensions of the annulus are such that the flow of red blood cells through it during decant is restricted such that they do not contaminate the decanted supernatant to any significant degree.


In another embodiment, the disk is arranged on the shaft such that, when the chamber is tilted for gravity decanting, the disk rotates such that one edge of the disk engages the wall of the chamber to block flow of red blood cells.


In either of these embodiments, the specific gravity of the disk and its shape may be chosen so that a major part of the upper surface lies just below the interface, thus facilitating release of the supernatant from the disk during decanting. This upper surface is also preferably curved to match the cylindrical shape the interface assumes during centrifugation.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1a is a longitudinal cross-section of a portion of a processing tube chamber and a separator disk in accordance with a first embodiment of the invention.



FIG. 1b is a transverse cross section taken along line 1b-1b of FIG. 1a.



FIG. 2a is a longitudinal cross-section of the embodiment of FIGS. 1a and 1b when the separator disk is tilted during decanting.



FIG. 2b is a transverse cross section taken along line 2b-2b of FIG. 2a.



FIG. 3a is a longitudinal cross-section of a second embodiment of the invention.



FIG. 3b is a transverse cross section taken along line 3b-3b of FIG. 3a.



FIG. 4 is a longitudinal cross-section of a third embodiment of the invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

With reference to FIGS. 1 and 2, one chamber 2 of a processing tube, such as that shown in the '331 Wells patent has a separator disk 4 in accordance with the invention supported therein by a central shaft 6. The shaft 6 is designed to direct fluid introduced into the chamber to the bottom of the chamber. This precludes the formation of an air bubble at the bottom of the chamber, particularly when the bottom of the chamber is tapered. Thus, fluid is introduced into the chamber by inserting a cannula attached to a syringe containing blood into the shaft 6 and discharging the blood from the syringe into the chamber. A central opening 8 in the disk receives the shaft 6 in such a manner that the disk easily slides along the shaft.


The shaft 6 may not be necessary in all instances, for example, when the bottom of the processing tube is flat. In that instance the disk does not have a central hole.


The disk is preferably made of material having a specific gravity that allows the disk to float at the interface with red blood cells. In the preferred embodiment that specific gravity is about 1.04 (e. g., polystyrene), which is just less than the specific gravity of red blood cells at 70% hematocrit. Thus, when the blood is centrifuged, the disk moves to the interface between the red blood cells and the other components.


The interface will naturally assume a cylindrical shape with a cylindrical radius equal to the distance to the center of rotation of the centrifuge. The disk may be cylindrical, to match the shape of the interface.


In the embodiment shown in FIGS. 1a, 1b, 2a and 2b, the diameters of the hole 8 and the shaft 6 are such that an annular gap 10 is formed between the outer surface of the shaft and the interior surface of the hole 8. Similarly, an annular gap 12 is provided between the perimeter of the disk and the interior surface of the tube 2.



FIGS. 1
a and 1b illustrate the position of the disk during centrifugation, and it will be appreciated that the gaps 10 and 12 are large enough to allow passage of the descending heavier components, e. g., red blood cells and the ascending lighter components, e. g., plasma. According to this embodiment, however, the diameter of the central opening 8 is large enough whereby during decanting the disk 4 rotates as shown in the figures.


Thus, when the processing tube is rotated to the decant position, the more dense red blood cells, illustrated at 14, that have accumulated below the disk exert a force against the bottom of the disk as they try to flow through the gap 12. This causes the disk 4 to rotate, as shown in FIGS. 2a and 2b, until a portion of the lower outer edge 16 of the disk and also the upper outer edge 18 engage the inner surface of the chamber 2. This engagement between the edge 16 of the disk and the interior of the chamber effectively forms a valve that prevents flow of the red blood cells, allowing decant of the plasma supernatant without contamination by red blood cells. It will be appreciated that this embodiment requires the transverse dimension of the disk between edges 16 and 18 to be greater than the internal diameter of the tube so that the edges engage the interior of the tube when tilted.


A second embodiment is shown in FIGS. 3a and 3b. According to this embodiment, the gap 10 is made to be small whereby the disk does not rotate appreciably during decant, in contrast to the embodiment of FIGS. 1 and 2. It will be appreciated that an annular channel is formed by the gap 12, this channel having a width equal to the radial dimension of the gap and a length equal to the thickness of the disk at the edge. The rate of flow of a fluid through this channel is a function of the dimensions of the channel, and the dimensions of the disk of this embodiment are such that the red blood cells will not flow appreciably through the channel at 1G. In the preferred embodiment, the width of the gap is about 0.005 inch to about 0.020 inch, and the length is about 0.1 inch to about 0.3 inch.


Thus, the components of the blood flow through the channel during centrifugation (i. e., at 1000 G), but do not flow appreciably through the channel during decanting at 1 G. This allows the supernatant to be decanted without significant contamination by the red blood cells.



FIG. 4 illustrates a preferred shape of the disk 4. In this embodiment, the top surface 20 of the disk is concave, preferably cylindrical, and the disk is provided with an elongated central portion 22. The specific gravity of the disk material is selected so that the concave surface 20 is located just below the interface. That is, the thickness of the outer edge, the length of the portion 22, and the specific gravity of the material are chosen so that the center of buoyancy of the disk is just above the concave surface, and that surface will be just below the interface 26 with red blood cells. This arrangement allows a small layer 24 of the red blood cells to form on the upper surface.


The layer of red blood cells 24 reduces the surface tension between the platelets at the interface 26 and the surface 20 of the disk and facilitates release of the platelets from the disk. This is important to ensure that all of the platelets are decanted, and the small amount of red blood cells that may be decanted along with the supernatant does not generally represent a significant contamination of the supernatant.


Modifications within the scope of the appended claims will be apparent to those of skill in the art.

Claims
  • 1. A method of accumulating a small layer of red blood cells on an accumulating surface of a floating separator structure contained in a cavity of a container for a physiological fluid, the method comprising: containing the physiological fluid in the cavity of the container to be subjected to centrifugation, the physiological fluid including the red blood cells and the at least one desired component; andsubjecting the physiological fluid in the container to centrifugation to provide a separated physiological fluid wherein the floating separator structure includes the accumulating surface and a center of buoyancy in the separated physiological fluid, and wherein the arrangement of the accumulating surface relative to the center of buoyancy of the floating separator structure in the separated physiological fluid is such that, after centrifugation of the physiological fluid, at least a major portion of the accumulating surface is just below a small layer of red blood cells and the accumulating surface has accumulated the small layer of red blood cells.
  • 2. The method of claim 1, wherein the red blood cells reduce the surface tension between the at least one desired component and the accumulating surface, thereby facilitating release of the desired component from the accumulating surface.
  • 3. The method of claim 2, wherein the floating separator structure fits into the container such that a gap is formed between the perimeter of the floating separator structure and the interior of the container, the gap being of such a dimension that the red blood cells below the floating separator structure, during said subjecting the physiological fluid in the container to centrifugation, do not flow appreciably through the gap at about 1 G.
  • 4. The method of claim 1, wherein the floating separator structure comprises a central aperture and a raised outer periphery.
  • 5. The method of claim 4, wherein the accumulating surface of the separator structure is curved.
  • 6. The method of claim 4, wherein the accumulating surface of the separator structure is angled relative to a horizontal cross section of the separator structure.
  • 7. The method of claim 4, wherein the accumulating surface of the floating separator structure is bounded by the raised outer periphery and is closed from the central aperture so that the accumulating surface accumulates the small layer of red blood cells.
  • 8. The method of claim 4, wherein the floating separator structure is shaped such that its center of buoyancy in the separated physiological fluid is located above the accumulating surface of the separator structure so that, after centrifugation of the physiological fluid, the accumulating surface has accumulated the small layer of red blood cells.
  • 9. A method of using a combination of a container that forms a cavity adapted to contain a physiological fluid, and a floating separator structure contained in the cavity of the container, the method comprising: containing the physiological fluid in the cavity of the container to be subjected to centrifugation, the physiological fluid including the red blood cells and the at least one desired component; andsubjecting the physiological fluid in the container to centrifugation to provide a separated physiological fluid wherein the floating separator structure in the cavity includes: an accumulating surface that defines at a least a portion of a closed recess, and a shape and material that define a center of buoyancy of the floating separator structure in the separated physiological fluid within the container, and wherein the arrangement of the accumulating surface relative to the center of buoyancy of the floating separator structure in the separated physiological fluid is such that, after centrifugation of the physiological fluid, at least a major portion of the accumulating surface is just below a small layer of red blood cells and accumulates the small layer of red blood cells.
  • 10. The method of claim 9, wherein the red blood cells reduce the surface tension between the at least one desired component and the accumulating surface, thereby facilitating release of the desired component from the accumulating surface.
  • 11. The method of claim 10, wherein the floating separator structure fits into the container such that a gap is formed between the perimeter of the floating separator structure and the interior of the container, the gap being of such a dimension that the red blood cells below the floating separator structure, during said subjecting the physiological fluid in the container to centrifugation, do not flow appreciably through the gap at about 1 G.
  • 12. The method of claim 11, wherein the accumulating surface of the separator structure is curved.
  • 13. The method of claim 11, wherein the accumulating surface of the separator structure is angled relative to a horizontal cross section of the separator structure.
  • 14. The method of claim 9, wherein the floating separator structure is shaped such that its center of buoyancy in the separated physiological fluid is located above the accumulating surface of the separator structure so that, after centrifugation of the physiological fluid, the accumulating surface has accumulated the small layer of red blood cells.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. application Ser. No. 14/160,809 filed on Jan. 22, 2014, which is a continuation of U.S. application Ser. No. 13/680,350 filed on Nov. 19, 2012, which is a continuation of U.S. application Ser. No. 12/453,577 filed on May 15, 2009, which is a divisional of U.S. application Ser. No. 11/206,869 filed Aug. 19, 2005, now U.S. Pat. No. 7,547,272, which is a divisional of U.S. application Ser. No. 10/019,680 filed Jan. 4, 2002, now U.S. Pat. No. 7,077,273, which was the national stage of International Application No. PCT/US01/11732 filed Apr. 27, 2001, which was published in English, and claims priority of U.S. Provisional Application No. 60/200,150 filed Apr. 28, 2000. This invention relates to methods and apparatus for use in the separation of fluids into components having different specific gravities. The invention finds particular utility in the centrifugal separation of the components of blood.

US Referenced Citations (89)
Number Name Date Kind
10140 Thompson, Jr. Oct 1853 A
280820 Hickson Jul 1883 A
593333 Park Nov 1897 A
1818924 Basmadjian Aug 1931 A
3256977 Petterson Jun 1966 A
3409165 Creith Nov 1968 A
3508653 Coleman Apr 1970 A
3618810 Wilson Nov 1971 A
3647070 Adler Mar 1972 A
3661265 Greenspan May 1972 A
3814248 Lawhead Jun 1974 A
3814258 Ayres Jun 1974 A
3852194 Zine Dec 1974 A
3887466 Ayres Jun 1975 A
3894950 Ayres Jul 1975 A
3894951 Ayres Jul 1975 A
3894952 Ayres Jul 1975 A
3897337 Ayres Jul 1975 A
3897343 Ayres Jul 1975 A
3897940 Gele Aug 1975 A
3909419 Ayres Sep 1975 A
3919085 Ayres Nov 1975 A
3920557 Ayres Nov 1975 A
3929646 Adler Dec 1975 A
3931010 Ayres Jan 1976 A
3931018 North Jan 1976 A
3931928 Kido Jan 1976 A
3935113 Ayres Jan 1976 A
3941699 Ayres Mar 1976 A
3945928 Ayres Mar 1976 A
3951801 Ayres Apr 1976 A
3957654 Ayres May 1976 A
3972812 Gresl, Jr. Aug 1976 A
4001122 Griffin Jan 1977 A
4055501 Cornell Oct 1977 A
4083788 Ferrara Apr 1978 A
4088582 Murty et al. May 1978 A
4152270 Cornell May 1979 A
4154690 Ballies May 1979 A
4169060 Columbus Sep 1979 A
4180465 Murty Dec 1979 A
4279863 Friehler Jul 1981 A
4294707 Ikeda et al. Oct 1981 A
4310430 Ichikawa Jan 1982 A
4364832 Ballies Dec 1982 A
4369117 White Jan 1983 A
4417981 Nugent Nov 1983 A
4443345 Wells Apr 1984 A
4487700 Kanter Dec 1984 A
4492634 Villa-Real Jan 1985 A
4563332 Mitchell et al. Jan 1986 A
4588556 Sarstedt May 1986 A
4608178 Johansson Aug 1986 A
4707276 Dodge Nov 1987 A
4751001 Saunders Jun 1988 A
4818386 Burns Apr 1989 A
4824560 Alspector Apr 1989 A
4844818 Smith Jul 1989 A
4853137 Ersson Aug 1989 A
4877520 Burns Oct 1989 A
4946601 Fiehler Aug 1990 A
4954264 Smith Sep 1990 A
5053134 Luderer et al. Oct 1991 A
5282981 Adams et al. Feb 1994 A
5314074 Inbar et al. May 1994 A
5316779 Morey May 1994 A
5389265 Luoma, II Feb 1995 A
5393674 Levine et al. Feb 1995 A
5454958 Fiehler Oct 1995 A
5456885 Coleman et al. Oct 1995 A
5533518 Vogler Jul 1996 A
5552325 Nochumson Sep 1996 A
5560830 Coleman Oct 1996 A
5577513 Van Vlasselaer Nov 1996 A
5632895 Tsukagoshi et al. May 1997 A
5632905 Haynes May 1997 A
5707331 Wells Jan 1998 A
5707876 Levine Jan 1998 A
5736033 Coleman et al. Apr 1998 A
5785925 U'Ren Jul 1998 A
5840502 Van Vlasselaer Nov 1998 A
5860937 Cohen Jan 1999 A
5889584 Wardlaw Mar 1999 A
5918622 Perez Jul 1999 A
6280400 Niermann Aug 2001 B1
6641517 Anderson Nov 2003 B2
7077273 Ellsworth et al. Jul 2006 B2
7547272 Ellsworth Jun 2009 B2
RE43547 Ellsworth Jul 2012 E
Foreign Referenced Citations (7)
Number Date Country
89 10 591.5 Dec 1989 DE
1 106 252 Jun 2001 EP
1 129 779 Sep 2001 EP
S64-044850 Dec 1981 JP
S56-168814 Feb 1989 JP
52-126613 Oct 1997 JP
7900135 Mar 1979 WO
Non-Patent Literature Citations (22)
Entry
Order Construing the Terms of U.S. Pat. Nos. 7,077,273 and RE43,547, DE 65, Filed Sep. 22, 2014.
Robert E. Marx et al., “Platelet-rich plasma. Growth factor enhancement for bone grafts”, Oral and Maxillofacial Surgery, University of Miami School of Medicine, Jan. 1998.
Complaint for Patent Infringement, DE 1, 1-1 -1-3 (Exhibits A-C), Filed Oct. 24, 2012.
Report to the PTO, DE 3, Filed Oct. 24, 2012.
Amended Complaint for Patent Infringement, DE 5, 5-1 (Exhibits A-E), Filed Feb. 15, 2013.
Celling Technologies, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, DE 10, 10-1 (Exhibit A), Filed Apr. 11, 2013.
Defendant Thermogenesis Corp.'s Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, DE 12, 12-1 (Exhibit A), Filed Apr. 11, 2013.
Second Amended Complaint for Patent Infringement, DE 32, 32-1 (Exhibit A-E) Filed Jan. 10, 2014.
Amended Report to the PTO, DE 35, Filed Jan. 13, 2014.
Defendant Thermogenesis Corp.'s Answer, Defenses, and Counterclaims to Plaintiff's Second Amended Complaint, DE 37, Filed Feb. 28, 2014.
Celling Technologies, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Second Amended Complaint, DE 38, Filed Feb. 28, 2014.
Cesca's Therapeutics Inc., and Celling Technologies, LLC's Response to Plaintiff Harvest Technologies Corporation's First Set of Joint Interrogatories to Defendants Cesca Therapeutics Inc. and Celling Technologies, LLC (Nos. 1-6), May 1, 2014.
Joint Claim Chart, DE 49, 49-1, Filed May 21, 2014.
Defendants Cesca's and Ceiling's Opening Claim Construction Brief, DE 50, Filed May 30, 2014 33. Harvest Technologies Corporation's Opening Claim Construction Brief, DE 51, Filed May 30, 2014.
Amended Joint Claim Chart, DE 52, 52-1 (Exhibit A), Filed Jun. 9, 2014.
Defendants Cesca's and Ceiling's Answering Claim Construction Brief, DE 54, Filed Jun. 27, 2014.
Harvest Technologies Corporation's Answering Claim Construction Brief, DE 55, Filed Jun. 27, 2014.
Joint Appendix of Intrinsic Evidence, DE 56, 56-1-56-22, Filed Jun. 27, 2014.
Harvest Markman Hearing Transcript, DE 58, Jul. 9, 2014.
Cesca Therapeutics Inc.'s First Supplemental Responses to Plaintiff Harvest Technologies Corporation's First Set of JT Interrogatories to Defendants Cesca Therapeutics Inc. and Celling Technologies, LLC (Nos. 1-6) (Appendices B01-08 and C), filed Dec. 19, 2014.
Celling Technologies, LLC's First Supplemental Responses to Plaintiff Harvest Technologies Corporation's First Set of JT Interrogatories to Defendants Cesca Therapeutics Inc. and Celling Technologies, LLC (Nos. 1-6) (Appendices B01-08) and C, filed Dec. 19, 2014.
Stipulated Motion and [Proposed] Order for Dismissal With Prejudice, filed Aug. 20, 2015, 2 pages.
Related Publications (1)
Number Date Country
20150290661 A1 Oct 2015 US
Provisional Applications (1)
Number Date Country
60200150 Apr 2000 US
Divisions (3)
Number Date Country
Parent 14160809 Jan 2014 US
Child 14750412 US
Parent 11206869 Aug 2005 US
Child 12453577 US
Parent 10019680 US
Child 11206869 US
Continuations (2)
Number Date Country
Parent 13680350 Nov 2012 US
Child 14160809 US
Parent 12453577 May 2009 US
Child 13680350 US